Tranylcypromine and the Extrapyramidal Syndromes *

Barbeau A. Preliminary Observations on Abnormal Catecholamine Metabolism in Basal Ganglia Diseases, Neurology 10:446–451, 1960.

Barbeau A. , and Sourkes T. L. Biochemical Aspects of Extrapyramidal Syndromes, Int. Symp. on the Extrapyramidal System and Neuroleptics, Montreal, November 1960. Rev. Can. de Biol. 20–197, 1961.

Barbeau A. Dopamine and Basal Ganglia Diseases, Arch, of Neurol. 4:97–102, 1961.

Barbeau A. , Murphy G. F. , and Sourkes T. L. Excretion of Dopamine in Diseases of Basal Ganglia, Science 133: 1706–1961.

Barbeau A. , and Duchastel Y. , Sourkes T. L. , and Murphy G. F. Dopamine and Diseases of the Basal Ganglia, 13th Annual Meeting of the American Academy of Neurology, Detroit, April 29, 1961. Submitted for publication in Neurology.

Burns B. D. , and De Jong J. D. A Preliminary Report on the Measurement of Parkinson's Disease, Neurology 10:1096–1102, 1960.

England A. C. , and Schwab R. S. The Management of Parkinson's Disease, A.M.A. Arch. Int. Med., 104:439–468, 1959.

Ehringer H. , and Hornykiewicz O. Verteilung von Noradrenalin und Dopamin (3-Hydroxytyramin) im Gehirn des Menschen und Ihr Verhalten bein Erkrankungen des Extra-pyramidalen Systems, Klinische Wochenschrift 38: 1236–1239, 1960.

Schiele B. C. Specific Therapeutic Properties of Tranylcypromine and of Trifluoperazine, Am. J. Psychiat., 117:245–246, 1960.

Sourkes T. L. Formation of Dopamine in vivo: Relation to the Function of the Basal Ganglia, Int. Symp. on the Extrapyramidal System and Neuroleptics, Montreal, November 1960, Rev. Can. de Biol. 20:187, 1961.

Tedeschi R. E. , Tedeschi D. H. , Ames P. L. , Cook L. , Mattis P. A. , and Fellows E. J. Some Pharmacologic Observation of Tranylcypromine (SKF trans-385) a Potent Inhibitor of Mono-amine Oxidase, Troc. Soc. Exp. Biol. & Med., 102:380, 1959.